Patents by Inventor Tomoaki Hasui

Tomoaki Hasui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused heterocyclic compounds
    Patent number: 9029536
    Abstract: The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: May 12, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Joseph Raker, Takahiko Taniguchi, Masato Yoshikawa, Tomoaki Hasui, Jun Kunitomo
  • Fused heterocyclic compounds
    Patent number: 8940758
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: January 27, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiko Taniguchi, Masato Yoshikawa, Kasei Miura, Tomoaki Hasui, Eiji Honda, Keisuke Imamura, Makoto Kamata, Haruhi Ando
  • Fused heterocyclic ring compound
    Patent number: 8883788
    Abstract: Provided is a compound having a PDE10A inhibitory action, and useful as a medicament for the prophylaxis or treatment of mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: November 11, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tomoaki Hasui, Makoto Fushimi, Hironori Kokubo, Takenori Hitaka, Shotaro Miura, Takahiko Taniguchi
  • Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors
    Patent number: 8846713
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: September 30, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiko Taniguchi, Masato Yoshikawa, Kasei Miura, Tomoaki Hasui, Eiji Honda, Keisuke Imamura, Makoto Kamata
  • FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS
    Publication number: 20140228320
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):
    Type: Application
    Filed: April 15, 2014
    Publication date: August 14, 2014
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Takahiko TANIGUCHI, Masato YOSHIKAWA, Kasei MIURA, Tomoaki HASUI, Eiji HONDA, Keisuke IMAMURA, Makoto KAMATA, Haruhi KAMISAKI, John F. QUINN, Joseph RAKER, Fatoumata CAMARA, Yi WANG
  • RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS
    Publication number: 20140178304
    Abstract: The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of PDE10A in mammals. The compound of the present invention is represented by the formula (I): wherein each symbols are as defined in the specification.
    Type: Application
    Filed: August 21, 2012
    Publication date: June 26, 2014
    Inventors: Takahiko Taniguchi, Shotaro Miura, Tomoaki Hasui, Christer Halldin, Vladimir Stepanov, Akihiro Takano
  • CONDENSED HETEROCYCLIC COMPOUND
    Publication number: 20130331409
    Abstract: The present invention provides a compound having a superior PDE10A inhibitory action and use thereof. The compound is a compound represented by the following formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Application
    Filed: March 15, 2012
    Publication date: December 12, 2013
    Inventors: Takahiko Taniguchi, Jun Kunitomo, Masato Yoshikawa, Tomoaki Hasui, Eiji Honda, Keisuke Imamura, Haruhi Kamisaki, Shinkichi Suzuki, Kasei Miura
  • FUSED HETEROCYCLIC COMPOUNDS
    Publication number: 20130303553
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 14, 2013
    Inventors: Takahiko TANIGUCHI, Masato YOSHIKAWA, Kasei MIURA, Tomoaki HASUI, Eiji HONDA, Keisuke IMAMURA, Makoto KAMATA, Haruhi KAMISAKI
  • Fused heterocyclic compounds
    Patent number: 8563575
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: October 22, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiko Taniguchi, Masato Yoshikawa, Kasei Miura, Tomoaki Hasui, Eiji Honda, Keisuke Imamura, Makoto Kamata, Haruhi Kamisaki
  • FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS
    Publication number: 20130172328
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):
    Type: Application
    Filed: June 22, 2011
    Publication date: July 4, 2013
    Applicant: CROSSWING INC.
    Inventors: Takahiko Taniguchi, Masato Yoshikawa, Kasei Miura, Tomoaki Hasui, Eiji Honda, Keisuke Imamura, Makoto Kamata, Haruhi Kamisaki, John F. Quinn, Joseph Raker, Fatoumata Camara, Yi Wang
  • FUSED HETEROCYCLIC COMPOUNDS
    Publication number: 20130172292
    Abstract: The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on.
    Type: Application
    Filed: August 3, 2011
    Publication date: July 4, 2013
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Joseph Raker, Takahiko Taniguchi, Masato Yoshikawa, Tomoaki Hasui, Jun Kunitomo
  • HETEROCYCLIC COMPOUND
    Publication number: 20130150344
    Abstract: The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.
    Type: Application
    Filed: August 3, 2011
    Publication date: June 13, 2013
    Inventors: Masato Yoshikawa, Shinkichi Suzuki, Tomoaki Hasui, Makoto Fushimi, Jun Kunitomo, Haruhi Kamisaki, Takahiko Taniguchi
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20130137675
    Abstract: The present invention aims to provide a compound having a PDE inhibitory action and useful as a medicament for the prophylaxis or treatment of schizophrenia and the like. A compound represented by the formula (1x): wherein each symbol is as described in the DESCRIPTION, or the formula (1): W1—W2??(1) wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: August 9, 2011
    Publication date: May 30, 2013
    Inventors: Takahiko Taniguchi, Shinkichi Suzuki, Masato Yoshikawa, Tomoaki Hasui, Makoto Fushimi, Jun Kunitomo
  • FUSED HETEROCYCLIC RING COMPOUND
    Publication number: 20130137700
    Abstract: Provided is a compound having a PDE10A inhibitory action, and useful as a medicament for the prophylaxis or treatment of mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: August 3, 2011
    Publication date: May 30, 2013
    Inventors: Tomoaki Hasui, Makoto Fushimi, Hironori Kokubo, Takenori Hitaka, Shotaro Miura, Jun Kunitomo, Takahiko Taniguchi
  • FUSED HETEROCYCLIC COMPOUNDS
    Publication number: 20110319394
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.
    Type: Application
    Filed: June 22, 2011
    Publication date: December 29, 2011
    Inventors: Takahiko TANIGUCHI, Masato YOSHIKAWA, Kasei MIURA, Tomoaki HASUI, Eiji HONDA, Keisuke IMAMURA, Makoto KAMATA, Haruhi KAMISAKI, John F. QUINN, Joseph RAKER, Fatoumata CAMARA, Yi WANG
  • PYRAZOLE COMPOUNDS
    Publication number: 20100094000
    Abstract: The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineralocorticoid receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of a disease or condition mediated by the mineralocorticoid receptor activation.
    Type: Application
    Filed: September 2, 2009
    Publication date: April 15, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shoji FUKUMOTO, Norio OHYABU, Taiichi OHRA, Takahiro SUGIMOTO, Tomoaki HASUI, Koji FUJI, Christopher S. SIEDEM, Cassandra GAUTHIER
  • Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands
    Publication number: 20090253687
    Abstract: The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.
    Type: Application
    Filed: December 27, 2006
    Publication date: October 8, 2009
    Inventors: Shoji Fukumoto, Nobuyuki Matsunaga, Taiichi Ohra, Norio Ohyabu, Tomoaki Hasui, Takashi Motoyaji, Christopher Stephen Siedem, Tony Pisal Tang, Lisa A. Demeese, Cassandra Gauthier